Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 14789
Country/Region: Mozambique
Year: 2016
Main Partner: Elizabeth Glaser Pediatric AIDS Foundation
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $21,895,240 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,663,104
Care: TB/HIV (HVTB) $351,027
Care: Pediatric Care and Support (PDCS) $405,890
Strategic Information (HVSI) $100,000
Health Systems Strengthening (OHSS) $30,000
Testing: HIV Testing and Counseling (HVCT) $1,710,540
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,834,092
Treatment: Adult Treatment (HTXS) $13,233,994
Treatment: Pediatric Treatment (PDTX) $1,566,593
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 130
GEND_GBV Age/Sex: <10 Male 2017 27
GEND_GBV Age/Sex: 10-14 Female 2017 604
GEND_GBV Age/Sex: 10-14 Male 2017 77
GEND_GBV Age/Sex: 15-19 Female 2017 604
GEND_GBV Age/Sex: 15-19 male 2017 77
GEND_GBV Age/Sex: 20-24 Female 2017 604
GEND_GBV Age/Sex: 20-24 Male 2017 77
GEND_GBV Age/Sex: 25-49 Female 2017 480
GEND_GBV Age/Sex: 25-49 Male 2017 27
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 1,207
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 4,864
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 1,634
GEND_GBV Number of people receiving post-GBV care 2017 6,460
GEND_GBV Sum of Age/Sex Disaggregates 2017 838
HRH_PRE By Graduates: Laboratory professionals 2017 30
HRH_PRE By Graduates: Nurses 2017 65
HRH_PRE By Graduates: Other 2017 36
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2017 131
HRH_PRE Sum of Graduates disaggregates 2017 131
HTS_TST Age/sex: <1 2017 3,660
HTS_TST Age/sex: 1-9 2017 14,779
HTS_TST Age/sex: 10-14 Female 2017 4,703
HTS_TST Age/sex: 10-14 Male 2017 8,513
HTS_TST Age/sex: 15-19 Female 2017 15,413
HTS_TST Age/sex: 15-19 Male 2017 6,078
HTS_TST Age/sex: 20-24 Female 2017 22,765
HTS_TST Age/sex: 20-24 Male 2017 5,958
HTS_TST Age/sex: 25-49 Female 2017 37,151
HTS_TST Age/sex: 25-49 Male 2017 10,695
HTS_TST Age/sex: 50+ Female 2017 3,872
HTS_TST Age/sex: 50+ Male 2017 2,251
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 884
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 60,474
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 642
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 55,186
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 6,555
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 252,750
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 899
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 77,263
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 8,980
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 445,571
HTS_TST Service Delivery Point (Community): Index testing 2017 33,680
HTS_TST Service Delivery Point (Community): Other 2017 2,818
HTS_TST Service Delivery Point (Facility): Index testing 2017 33,681
HTS_TST Service Delivery Point (Facility): Other PITC 2017 145
HTS_TST Service Delivery Point (Facility): Other PITC 2017 7,036
HTS_TST Service Delivery Point (Facility): Outpatient 2017 5,509
HTS_TST Service Delivery Point (Facility): Outpatient 2017 235,636
HTS_TST Service Delivery Point (Facility): Pediatric 2017 225
HTS_TST Service Delivery Point (Facility): Pediatric 2017 15,474
HTS_TST Service Delivery Point (Facility): PMTCT 2017 3,068
HTS_TST Service Delivery Point (Facility): PMTCT 2017 52,039
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 33
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2,227
HTS_TST Service Delivery Point (Facility): VCT 2017 62,980
HTS_TST Sum of Age/Sex disaggregates 2017 117,399
HTS_TST Sum of Aggregated Age/Sex <15 2017 1,526
HTS_TST Sum of Aggregated Age/Sex <15 2017 115,660
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 7,454
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 330,013
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 8,980
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 445,673
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 350
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 227
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 1,269
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 423
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 2,831
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 1,050
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 6,774
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 4,634
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 995
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 987
HTS_TST_POS Test Result by Age: Positive: <1 2017 308
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 1,343
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 37
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 4,303
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 29
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 3,714
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 627
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 39,353
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 189
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 23,571
PMTCT_ART Already on ART at beginning of current pregnancy 2017 207
PMTCT_ART Already on ART at beginning of current pregnancy 2017 4,140
PMTCT_ART New on ART 2017 310
PMTCT_ART New on ART 2017 6,222
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 3,336
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 56,712
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 289
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 6,661
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 130
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 2,996
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 10
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 238
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 14
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 337
PMTCT_EID Sum of Infant Age disaggregates 2017 419
PMTCT_EID Sum of Infant Age disaggregates 2017 9,657
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 660
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 5,717
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 7,754
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 10,379
PMTCT_STAT By Age (DREAMS SNUs ONLY): 50+ 2017 19
PMTCT_STAT By: Known positives at entry 2017 209
PMTCT_STAT By: Known positives at entry 2017 4,187
PMTCT_STAT By: Number of new positives identified 2017 313
PMTCT_STAT By: Number of new positives identified 2017 6,282
PMTCT_STAT Number of new ANC and L&D clients 2017 3,369
PMTCT_STAT Number of new ANC and L&D clients 2017 57,283
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 3,336
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 56,712
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 186
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 557
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 1,101
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 18
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: <15 2017 5
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 415
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 919
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 1,425
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 26
PMTCT_STAT Sum of Positives Status disaggregates 2017 522
PMTCT_STAT Sum of Positives Status disaggregates 2017 10,469
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 668
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 5,775
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 7,832
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 10,484
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 50+ 2017 21
PP_PREV Aggregated Age/sex: <15 Female 2017 3,544
PP_PREV Aggregated Age/sex: <15 Male 2017 8,267
PP_PREV Aggregated Age/sex: 15+ Female 2017 2,362
PP_PREV Aggregated Age/sex: 15+ Male 2017 3,544
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 11,811
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 82
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3,817
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 44
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2,058
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 126
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 5,875
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 126
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 5,875
TB_SCREENDX Screen Result: Screened Positive for TB 2017 11,339
TB_SCREENDX Screen Results: Screened Positive for TB 2017 206
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 130
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 130
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 1,503
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 85,580
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 810
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 46,083
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 5,069
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 5,069
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 2,570
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 141,752
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 129
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 5,460
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 69
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,937
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 198
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 8,397
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 198
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 8,397
TX_CURR Age/Sex: <1 2017 2
TX_CURR Age/Sex: <1 2017 215
TX_CURR Age/Sex: <1-9 2017 2,985
TX_CURR Age/Sex: 10-14 Female 2017 640
TX_CURR Age/Sex: 10-14 Male 2017 640
TX_CURR Age/Sex: 15-19 Female 2017 1,974
TX_CURR Age/Sex: 15-19 Male 2017 1,335
TX_CURR Age/Sex: 20-24 Female 2017 4,522
TX_CURR Age/Sex: 20-24 Male 2017 3,508
TX_CURR Age/Sex: 25-49 Female 2017 10,303
TX_CURR Age/Sex: 25-49 Male 2017 12,704
TX_CURR Age/Sex: 50+ Female 2017 1,641
TX_CURR Age/Sex: 50+ Male 2017 2,917
TX_CURR Aggregated Age/Sex: <15 Female 2017 115
TX_CURR Aggregated Age/Sex: <15 Female 2017 5,355
TX_CURR Aggregated Age/Sex: <15 Male 2017 115
TX_CURR Aggregated Age/Sex: <15 Male 2017 5,355
TX_CURR Aggregated Age/Sex: 15+ Female 2017 1,330
TX_CURR Aggregated Age/Sex: 15+ Female 2017 73,313
TX_CURR Aggregated Age/Sex: 15+ Male 2017 716
TX_CURR Aggregated Age/Sex: 15+ Male 2017 39,481
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 2,272
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 123,460
TX_CURR Sum of age/sex disaggregates 2017 3,309
TX_CURR Sum of Aggregated Age/Sex <15 2017 230
TX_CURR Sum of Aggregated Age/Sex <15 2017 10,710
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 2,046
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 112,794
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 2,276
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 123,504
TX_NEW Aggregated Grouping by Age: <1 2017 2
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 29
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 2,328
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 303
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 28,713
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 29
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 2,328
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 163
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 15,467
TX_NEW By Age/Sex: <1 2017 215
TX_NEW By Age/Sex: 1-9 2017 1,511
TX_NEW By Age/Sex: 10-14 Female 2017 319
TX_NEW By Age/Sex: 10-14 Male 2017 158
TX_NEW By Age/Sex: 15-19 Female 2017 775
TX_NEW By Age/Sex: 15-19 Male 2017 524
TX_NEW By Age/Sex: 20-24 Female 2017 1,777
TX_NEW By Age/Sex: 20-24 Male 2017 1,379
TX_NEW By Age/Sex: 25-49 Female 2017 4,048
TX_NEW By Age/Sex: 25-49 Male 2017 4,990
TX_NEW By Age/Sex: 50+ Female 2017 647
TX_NEW By Age/Sex: 50+ Male 2017 1,147
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 523
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 48,783
TX_NEW Sum of Age/Sex disaggregates 2017 15,764
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 524
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 48,836
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 865
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 35,886
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 649
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 26,915
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 49
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 2,385
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 361
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 14,433
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 49
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 2,385
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 194
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 7,769
TX_PVLS Numerator: Indication: Routine 2017 112
TX_PVLS Numerator: Indication: Routine 2017 5,284
TX_PVLS Numerator: Indication: Targeted 2017 537
TX_PVLS Numerator: Indication: Targeted 2017 21,631
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 64
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 3,169
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 64
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 3,169
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 480
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 19,238
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 258
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 10,363
TX_PVLS_den Denominator: Indication: Routine 2017 148
TX_PVLS_den Denominator: Indication: Routine 2017 7,041
TX_PVLS_den Denominator: Indication: Targeted 2017 717
TX_PVLS_den Denominator: Indication: Targeted 2017 28,845
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 292
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,111
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 295
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 144
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,282
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 399
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,937
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,049
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,690
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,801
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,067
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 874
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 103
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,746
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 455
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 22,727
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 103
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,746
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 245
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 12,236
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 904
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 38,408
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 1,292
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 49,553
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 321
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,221
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 325
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 162
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,409
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 437
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,231
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,154
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,363
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,179
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,171
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 960
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 149
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,258
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 649
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 29,312
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 149
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,258
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 349
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 15,784
Cross Cutting Budget Categories and Known Amounts Total: $1,407,312
Human Resources for Health $490,970
Gender: Gender Based Violence (GBV) $916,342
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation